The relationship between twenty missense ATM variants and breast cancer risk: The multiethnic cohort

Cancer Epidemiology Biomarkers and Prevention

Volumn 12, Issue 8, 2003, Pages 733-738

  Bretsky, Philip ^a   Haiman, Christopher A ^a   Gilad, Shlomit ^b   Yahalom, Joachim ^c   Grossman, Avital ^b   Paglin, Shoshana ^c   Van Den Berg, David ^a   Kolonel, Laurence N ^d   Skaliter, Rami ^b   Henderson, Brian E ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Quark Biotech Inc   (Israel)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF HAWAII CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; ASIA; ATAXIA TELANGIECTASIA; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; CAUCASIAN; CHROMOSOME ABERRATION; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA DAMAGE; DNA POLYMORPHISM; DNA REPAIR; ETHNOLOGY; FAMILIAL CANCER; FEMALE; GENETIC VARIABILITY; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MISSENSE MUTATION; NEGRO; POPULATION; PREDICTION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

AFRICAN AMERICANS; AGED; ASIAN AMERICANS; BREAST NEOPLASMS; CELL CYCLE PROTEINS; COHORT STUDIES; DNA-BINDING PROTEINS; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; JAPAN; MIDDLE AGED; MUTATION, MISSENSE; POLYMORPHISM, GENETIC; PROTEIN-SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS; VARIATION (GENETICS);

EID: 0041525364     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Boder, E. Ataxia-telangiectasia: an overview. In: R. A. Gatti (ed.), Ataxia-Telangiectasia: Genetics, Neuropathology and Immunology of a Degenerative Disease of Childhood, pp. 1-63. New York: Alan R. Liss, 1985.
2. Shiloh, Y. Ataxia-telangiectasia: closer to unraveling the mystery. Eur. J. Hum. Genet., 3: 116-138, 1995.
3. Savitsky, K., Bar-Shira, A., Gilad, S., Rotman, G., Ziv, Y., Vanagaite, L., Tagle, D. A., Smith, S., Uziel, T., Sfez, S., Ashkenazi, M., Pecker, I., Frydman, M., Harnik, R., Patanjali, S. R., Simmons, A., Clines, G. A., Sartiel, A., Gatti, R. A., Chessa, L., Sanal, O., Lavin, M. F., Jaspers, N. G. J., Taylor, M. R., Arlett, C. F., Miki, T., Weissman, S. M., Lovett, M., Collins, F. S., and Shiloh, Y. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science (Wash. DC), 268: 1749-1753, 1995.
4. Savitsky, K., Sfez, S., Tagle, D. A., Ziv, Y., Sartiel, A., Collins, F. S., Shiloh, Y., and Rotman, G. The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species. Hum. Mol. Genet., 4: 2025-2032, 1995.
5. Gilad, S., Khosravi, R., Shkedy, D., Uziel, T., Ziv, Y., Savitsky, K., Rotman, G., Smith, S., Chessa, L., Jorgensen, T. J., Harnik, R., Frydman, M., Sanal, O., Portnoi, S., Goldwicz, Z., Jaspers, N. G. J., Gatti, R. A., Lenoir, G., Lavin, M. F., Tatsumi, J., Wegner, R. D., Shiloh, Y., and Bar-Shira, A. Predominance of null variants in ataxia-telangiectasia. Hum. Mol. Genet., 3: 433-439, 1996.
6. Morgan, J. L., Holcomb, T. M., and Morrissey, R. W. Radiation reaction in ataxia telangiectasia. Am. J. Dis. Child., 116: 557-558, 1968.
7. Eyra, J. A., Gardner-Medwin, D., and Summerfield, G. P. Leukoencephalopathy after prophylactic radiation for leukaemia in ataxia telangiectasia. Arch. Dis. Child., 63: 1079-1080, 1988.
8. Gotoff, S. P., Amirmokri, E., and Liebner, E. J. Neoplasia, untoward response to X-irradiation, and tuberous sclerosis. Am. J. Dis. Child., 114: 617-625. 1967.
9. Arlett, C. F., Green, M. H., Priestley, A., Harcourt, S. A., and Mayne, L. V. Comparative human cellular radiosensitivity. I. The effect of SV40 transformation and immortalisation on the γ-irradiation survival of skin derived fibroblasts from normal individuals and from ataxia-telangiectasia patients and heterozygotes. Int. J. Radiat. Biol., 54: 911-928, 1988.
10. 0) T-lymphocytes, T-lymphocyte lines, lymphoblastoid cell lines and fibroblasts from normal donors, from ataxia-telangiectasia patients and from ataxia-telangiectasia heterozygotes. Int. J. Radiat. Biol., 54: 929-943, 1988.
11. Kastan, M. B., Zhan, Q., el-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., and Fornace, A. J. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell, 71: 587-597, 1992.
12. Morgan, S. E., and Kastan, M. B. p53 and ATM: cell cycle, cell death, and cancer. Adv. Cancer Res., 71: 1-25, 1997.
13. Canman, C. E., Lim, D. S., Cimprick, K. A., Taya, Y., Tamai, K., Sakaguchi, K., Appella, E., Kastan, M. B., and Siliciano, J. D. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science (Wash. DC), 281: 1677-1679, 1998.
14. Baskaran, R., Wood, L. D., Whitaker, L. L., Canman, C. E., Morgan, S. E., Xu, Y., Barlow, C., Baltimore, D., Wynshaw-Boris, A., Kasta, M. B., and Wang, J. Y. J. Ataxia telangiectasia mutant protein activates c-Abl tyrosine in response to ionizing radiation. Nature (Lond.), 387: 516-519, 1997.
15. Shafman, T., Khanna, K. K., Kedar, P., Spring, K., Kozlov, S., Yen, T., Hobson, K., Gatei, M., Zhang, N., Watters, D., Egerton, M., Shiloh, Y., Kharbanda, S., Kufe, D., and Lavin, M. F. Interaction between ATM protein and c-Abl in response to DNA damage. Nature (Lond.), 387: 520-523, 1997.
16. Chaturvedi, P., Eng, W. K., Zhu, Y., Mattern, M. R., Mishra, R., Hurle, M. R., Zhang, X., Annan, R. S., Lu, Q., Faucette, L. F., Scott, S. F., Li, X., Carr, S. A., Johnson, R. K., Winkler, J. D., and Zhou, B. B. S. Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene, 18: 4047-4054, 1999.
17. Matsuoka, S., Huang, M., and Elledge, S. J. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science (Wash. DC), 282: 1893-1897, 1998.
18. Blasina, C., Van de Weyer, I., Laus, M. C., Luyten, W. H. M. L., Parker, A. E., and McGowan, C. H. The human homologue of the checkpoint kinase Cds1 directly inhibits Cdc25 phosphatase. Cur. Biol., 9: 1-10, 1999.
19. Cortez, D., Wang, Y., Qin, J., and Elledge, S. J. Requirement of ATM-dependent phosphorylation of Brcal in the DNA damage response to double-strand breaks. Science (Wash. DC), 286: 1162-1166, 1999.
20. Concannon, P., and Gatti, R. A. Diversity of ATM gene variants detected in patients with ataxia-telangiectasia. Hum. Mutat., 10: 100-107, 1997.
21. Swift, M., Reitnauer, P. J., Morrell, D., and Chase, C. L. Breast and other cancers in families with ataxia-telangiectasia. N. Engl. J. Med., 316: 1289-1294, 1987.
22. Swift, M., Morrell, D., Massey, R. B., and Chase, C. L. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N. Engl. J. Med., 325: 1831-1836, 1991.
23. Athma, P., Rappaport, R., and Swift, M. Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet. Cytogenet., 92: 130-134, 1996.
24. Easton, D. F. Cancer risks in A-T heterozygotes. Int. J. Radiat. Biol., 66 (Suppl.): S177-S182, 1994.
25. Vorechovsky, I., Rasio, D., Luo, L., Monaco, C., Hammarstrom, L., Webster, A. D. B., Zaloudik, J., Barbanti-Brodano, G., James, M., Russo, G., Croce, C. M., and Negrini, M. The ATM gene and susceptibility to breast cancer: analysis of 38 breast tumors reveals no evidence for mutation. Cancer Res., 56: 2726-2732, 1996.
26. FitzGerald, M. G., Bean, J. M., Hegde, S. R., Unsal, H., MacDonald, D. J., Harkin, D. P., Finkelstein, D. M., Isselbacher, K. J., and Haber, D. A. Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat. Genet., 15: 307-310, 1997.
27. Gatti, R. A., Tward, A., and Concannon, P. Cancer risk in ATM heterozygotes: a model of phenotypic and mechanistic differences between missense and truncating mutations. Mol. Genet. Metab., 68: 419-423, 1999.
28. Dork, T., Bendix, R., Bremner, M., Rades, D., Klopper, K., Nicke, M., Skawran, B., Hector, A., Yamini, P., Steinmann. D., Weise, S., Stuhrmann, M., and Karstens, J. H. Spectrum of ATM gene mutations in a hospital-based series of unselected breast cancer patients. Cancer Res., 61: 7608-7615, 2001.
29. Sommer, S. S., Buzin, C. H., Jung, M., Zheng, J., Liu. Q., Jeong, S. J., Moulds, J., Nguyen, V. Q., Feng, J., Bennett, W. P., and Dritschilo, A. Elevated frequency of ATM gene missense mutations in breast cancer relative to ethnically matched controls. Cancer Genet. Cytogenet., 134: 25-32, 2002.
30. Teraoka, S. N., Malone, K. E., Doody, D. R., Suter, N. M., Ostrander, E. A., Daling, J, R., and Concannon, P. Increased frequency of ATM mutations in breast carcinoma patients with early onset disease and positive family history. Cancer (Phila.), 92: 479-487, 2001.
31. Stankovic, T., Kidd, A. M., Sutcliffe, A., McGuire, G. M., Robinson, P., Weber, P., Bedenham, T., Bradwell, A. R., Easton, D. F., Lennox, G. G., Haites, N., Byrd, P. J., and Taylor, A. M. ATM mutations and phenotypes in ataxiatelangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma and breast cancer. Am. J. Hum. Genet., 62: 334-345, 1998.
32. Chenevix-Trench, G., Spurdle, A. B., Gatei, M., Kelly, H., Marsh, A., Chen, X., Donn, K., Cummings, M., Nyholt, D., Jenkins, M. A., Scott, C., Pupo, G. M., Dork, T., Bendix, R., Kirk, J., Tucker, K., McCredie, M. R. E., Hopper, J. L., Sambrook, J., Mann, G. J., and Khanna, K. K. Dominant negative ATM mutations in breast cancer families. J. Natl. Cancer Inst. (Bethesda), 94: 205-215, 2002.
33. Scott, S. P., Bendix, R., Chen, P., Clark, R., Dork, T., and Lavin, M. F. Missense mutations but not allelic variants alter the function of ATM by dominant interference in patients with breast cancer. Proc. Natl. Acad. Sci. USA, 99: 925-930, 2002.
34. Spring, K., Ahangari, F., Scott, S. P., Waring, P., Purdie, D. M., Chen, P. C., Hourigan, K., Ramsay, J., McKinnon, P. J., Swift, M., and Lavin, M. F. Mice heterozygous for mutation in ATM, the gene involved in ataxia-telangiectasia, have heightened susceptibility to cancer. Nat. Genet., 32: 185-190, 2002.
35. Thorstenson, Y. R., Shen, P., Tusher, V. G., Wayne, T. L., Davis, R. W., Chu, G., and Oefner, P. J. Global constraint of ATM polymorphism reveals significant functional constraint. Am. J. Hum. Genet., 69: 396-412, 2001.
36. Kolonel, L. N., Henderson, B. E., Hankin, J. H., Nomura, A. M., Wilkens, L. R., Pike, M. C., Stram, D. O., Monroe, K. R., Earle, M. E., and Nagamine, F. S. A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am. J. Epidemiol., 151: 346-357, 2000.
37. Feigelson, H. S., McKean-Cowdin, R., Coetzee, G. A., Stram, D. O., Kolonel, L. N., and Henderson, B. E. Building a multigenic model of breast cancer susceptibility: CYP17 and HSD17B1 are two important candidates. Cancer Res., 61: 785-789, 2001.
38. McKean-Cowdin, R., Feigelson, H. S., Pike, M. C., Coetzee, G. A., Kolonel, L. N., and Henderson, B. E. Risk of endometrial cancer and estrogen replacement therapy history by CYP17 genotype. Cancer Res., 61: 848-849, 2001.
39. Vorechovsky, I., Ortmann, E. K., Steinmann, D., and Dork, T. Missense variants at ATM gene and cancer risk. Lancet, 353: 1276, 1999.
40. Stankovic, T., Weber, P., Stewart, G., Bedenham, T., Murray, J., Byrd, P. J., Moss, P. A., and Taylor, A. M. Inactivation of ataxia-telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia. Lancet, 353: 26-29, 1999.
41. Lee, L., Connell, C., and Bloch, W. Allelic discrimination by nick-translation PCR with fluorogenic probes. Nucleic Acids Res., 21: 3761-3766, 1993.
42. Broeks, A., Urbanus, J. H. M., Floore, A. N., Dahler, E. C., Klijn, J. G. M., Rutgers, E. J. T., Devilee, P., Russell, N. S., van Leeuwen, F. E., and van T Veer, L. J. ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. Am. J. Hum. Genet., 66: 494-500, 2000.
43. Bay, J., Uhrhammer, N., Pernin, D., Presneau, N., Tchirkov, A., Vuillaume, M., Laplace, V., Grancho, M., Verrele, P., Hall, J., and Bignon, Y. High incidence of cancer in a family segregating a mutation of the ATM gene: possible role of ATM heterozygosity in cancer. Hum. Mutat., 14: 485-492, 1999.
44. Chen, J. Birkholtz, G. G., Lindblom, P., Rubio, C., and Lindblom, A. The role of ataxia-telangiectasia heterozygotes in familial breast cancer. Cancer Res., 58: 1376-1379, 1998.
45. Bebb, D. G., Yu, Z., Chen, J., Telatar, M., Gilmon, K., Phillips, N., Gatti, R. A., and Glickman, B. W. Absence of mutations in the ATM gene in forty-seven cases of sporadic breast cancer. Br. J. Cancer, 80: 1979-1981, 1999.
46. Janin, N., Andrieu, N., Ossian, K., Lauge, A., Croquette, M-F., Griscelli, C., Debre, M., Bressac-de-Paillerets, B., Aurias, A., and Stoppa-Lyonnet, D. Breast cancer risk in ataxia telangiectasia (AT) heterozygotes: haplotype study in French AT families. Br. J. Cancer, 80: 1042-1045, 1999.
47. Olsen, J., Hahnemann, J., Borresen-Dale, A-L., Brondum-Nielsen, K., Hammarstrom, L., Kleinerman, R., Kaariainen H., Lonnqvist, T., Sankila, R., Seersholm, N., Tretli, S., Yuen, J., Boice, J., and Tucker, M. Cancer in patients with ataxia-telangiectasia and their relatives in the Nordic countries. J. Natl. Cancer Inst. (Bethesda), 93: 121-127, 2001.
48. Bonnen, P. E., Story, M. D., Ashom, C. L., Buchholz, T. A., Weil, M. M., and Nelson, D. L. Haplotypes at ATM identify coding-sequence variation and indicate a region of extensive linkage disequilibrium. Am. J Hum. Genet., 67: 1437-1451, 2000.
49. Khanna, K. K. Cancer risk and the ATM gene: a continuing debate. J. Natl. Cancer Inst. (Bethesda), 92: 795-802, 2000.
50. Wang, Y., Cortez, D., Yazdi, P., Neff, N., Elledge, S. J., and Qin, J. BASC, a super complex of BRCAI-associated proteins involvement in the recognition and repair of aberrant DNA structures. Genes Dev., 14: 927-939, 2000.
51. Elledge, S. J. Cell cycle checkpoints: preventing an identity crisis. Science (Wash. DC), 274: 1664-1671, 1996.
52. Pritchard, J. J., and Rosenberg, N. A . Use of unlinked genetic markers to detect population stratification in association studies. Am. J. Hum. Genet., 65: 220-228, 1999.